Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NXTC – Nextcure Inc

NextCure, Inc.
NXTC
$2.33
Name : NextCure, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $8,416,183.00
EPSttm : -16.82
finviz dynamic chart for NXTC
NextCure, Inc.
$2.33
16.49%
$0.46
NXTC — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.4

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.24

EPS Last/This Y

12.72

EPS This/Next Y

-1.42

Price

2.3

Target Price

19.33

Analyst Recom

1

Performance Q

-81.67

Upside

-10,739.9%

Beta

1.43

Ticker: NXTC




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11NXTC9.74N/AN/A0
2026-05-12NXTC9.9N/AN/A0
2026-05-13NXTC9.86N/AN/A0
2026-05-14NXTC10.11N/AN/A0
2026-05-15NXTC9.83N/AN/A0
2026-05-18NXTC9.32N/AN/A0
2026-05-19NXTC9.13N/AN/A0
2026-05-20NXTC9.81N/AN/A0
2026-05-21NXTC10.13N/AN/A0
2026-05-22NXTC7.84N/AN/A0
2026-05-26NXTC6.97N/AN/A0
2026-05-27NXTC6.07N/AN/A0
2026-05-28NXTC6.38N/AN/A0
2026-05-29NXTC6.18N/AN/A0
2026-06-02NXTC3.36N/AN/A0
2026-06-03NXTC3.23N/AN/A0
2026-06-04NXTC3.21N/AN/A0
2026-06-05NXTC2.91N/AN/A0
2026-06-08NXTC2.76N/AN/A0
2026-06-09NXTC2.32N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11NXTC9.8661.359.2-8.98
2026-05-12NXTC9.6256.6- -8.98
2026-05-13NXTC9.9056.6- -8.98
2026-05-14NXTC10.4856.6- -8.98
2026-05-15NXTC9.5156.6- -7.69
2026-05-18NXTC9.4183.7- -7.69
2026-05-19NXTC9.1783.7- -7.69
2026-05-20NXTC9.4383.5- -6.93
2026-05-21NXTC10.6083.5- -6.93
2026-05-22NXTC7.8483.5- -6.93
2026-05-26NXTC7.0283.5- -6.93
2026-05-27NXTC6.0383.5- -6.93
2026-05-28NXTC6.3483.5- -6.93
2026-05-29NXTC6.2683.5- -6.93
2026-06-01NXTC3.3883.5- -6.93
2026-06-02NXTC3.3783.5- -6.93
2026-06-03NXTC3.1683.5- -6.93
2026-06-04NXTC3.1983.5- -6.93
2026-06-05NXTC2.9183.5- -6.93
2026-06-08NXTC2.7583.5- -6.93
2026-06-09NXTC2.3083.5- -6.93
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11NXTC0.0017.302.99
2026-05-12NXTC0.0017.302.99
2026-05-13NXTC0.0017.302.99
2026-05-14NXTC0.0017.302.99
2026-05-15NXTC0.0017.302.99
2026-05-18NXTC0.0017.162.98
2026-05-19NXTC0.0017.162.98
2026-05-20NXTC0.0017.162.98
2026-05-21NXTC0.0017.162.98
2026-05-22NXTC0.0017.162.98
2026-05-26NXTC0.007.712.98
2026-05-27NXTC0.007.712.98
2026-05-28NXTC0.007.712.40
2026-05-29NXTC0.007.712.40
2026-06-02NXTC0.007.392.40
2026-06-03NXTC0.007.392.40
2026-06-04NXTC0.007.392.40
2026-06-05NXTC0.007.392.40
2026-06-08NXTC0.007.392.40
2026-06-09NXTC0.007.392.40
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.87

Avg. EPS Est. Current Quarter

-1.86

Avg. EPS Est. Next Quarter

-1.63

Insider Transactions

Institutional Transactions

7.39

Beta

1.43

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

18

Sentiment Score

24

Actual DrawDown %

97.9

Max Drawdown 5-Year %

-97.5

Target Price

19.33

P/E

Forward P/E

PEG

P/S

P/B

0.31

P/Free Cash Flow

EPS

-19.07

Average EPS Est. Cur. Y​

-6.93

EPS Next Y. (Est.)

-8.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.87

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

1.28

EBIT Estimation

NXTC Healthcare
$2.33
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
5/25
Volume
3/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
20.4
Range 1M
0%
🚀
Momentum Growth
Ride accelerating trends
N/A
40 /100
WEAK
Momentum
16/25
Growth
16/30
Estimates
0/20
Inst/Vol
8/15
Options
0/10
EPS Yr
62.7%
EPS NY
-13.9%
52W%
0%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +729.6% upside
Quality
2/30
Valuation
16/30
Growth
9/25
Stability
7/10
LT Trend
4/5
Upside
+729.6%
Quality
3
NextCure, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 40
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC

Latest News

Caricamento notizie per NXTC
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading